IOL Chemicals And Pharmaceuticals Ltd. Share Price

IOL Chemicals & Pharmaceuticals Ltd Company Analysis

IOLCP IOL Chemicals & Pharmaceuticals Ltd is an integrated pharmaceutical API and speciality chemicals manufacturer. Its pharmaceutical business focuses on active pharmaceutical ingredients (APIs), with ibuprofen historically being its flagship product. It also manufactures other APIs, including metformin and other therapeutic ingredients. Q2 FY27 performance: The company delivered a strong quarter, reporting revenue from operations of ₹795 crore, up 40.1% YoY. EBITDA increased 79.6% to ₹114.9 crore, while net profit more than doubled, rising 116.8% to ₹65 crore. EBITDA margin improved to 14.4% from 11.1% in Q2 FY26, indicating better operating efficiency and product realisations. For H1 FY27, revenue increased 38.6% to ₹1,551 crore and net profit grew 102.5% to ₹129.5 crore. Both the pharmaceutical and chemicals segments contributed to the growth. One particularly positive development is diversification. Non-ibuprofen APIs contributed 45% of pharmaceutical revenue in Q2 FY27, compared with 38% a year earlier, with this portfolio growing approximately 70% YoY. Overall view is that IOL Chemicals is showing a meaningful improvement in both growth and profitability. The reduction in dependence on ibuprofen is strategically important, while the speciality chemicals and CDMO businesses offer additional growth opportunities. However, investors should monitor API pricing cycles, raw-material costs, regulatory compliance, customer concentration and the returns generated by its expansion investments. The latest results are genuinely strong, but one exceptional half-year does not establish a sustainable earnings trajectory. Valuation should be assessed using the latest share price and updated earnings rather than assuming this profit growth will continue at the same rate.

IOL Chemicals & Pharmaceuticals : Q2FY27 results Highlights

DHARMESH BHATT (Research Analyst) SEBI Registration No. INH000009685 !IOLCP Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q2FY27 results : ----Standalone Financial Highlights: ---- Revenue from Operations: For Q2FY27, the standalone revenue from operations stood at Rs 795.03 crore, up 5.13% QoQ from Rs 756.26 crore in Q1FY27, and up 40.09% YoY from Rs 567.53 crore in Q2FY26. For H1FY27, standalone revenue from operations reached Rs 1,551.29 crore, a YoY increase of 38.60% from Rs 1,119.22 crore in H1FY26. Total Income : For Q2FY27, standalone total income was Rs 800.54 crore, increasing 4.72% QoQ compared to Rs 764.44 crore in Q1FY27, and increasing 39.37% YoY compared to Rs 574.41 crore in Q2FY26. For H1FY27, standalone total income registered at Rs 1,564.98 crore, a YoY increase of 38.07% from Rs 1,133.47 crore in H1FY26. Profit Before Tax (PBT): For Q2FY27, standalone PBT stood at Rs 87.25 crore, changing by 0.55% QoQ from Rs 86.77 crore in Q1FY27, and increasing 115.33% YoY from Rs 40.52 crore in Q2FY26. For H1FY27, standalone PBT recorded at Rs 174.02 crore, growing by 102.21% YoY against Rs 86.06 crore in H1FY26. Profit After Tax (PAT): For Q2FY27, standalone PAT arrived at Rs 65.03 crore, reflecting a 0.85% QoQ growth relative to Rs 64.48 crore in Q1FY27, and a 116.77% YoY increase compared to Rs 30.00 crore in Q2FY26. For H1FY27, standalone PAT stood at Rs 129.51 crore, expanding by 102.49% YoY over Rs 63.96 crore in H1FY26. Disclosure /Disclaimer Link: *****

Stock Outlook: IOL Chemicals and Pharmaceuticals Ltd.

IOL Chemicals and Pharmaceuticals Ltd. is a leading manufacturer of specialty chemicals and pharmaceutical products in India. The company specializes in producing active pharmaceutical ingredients (APIs), solvents, and other chemicals, focusing on quality and innovation to meet diverse industry needs. Iol Chemicals & Pharms. has an operating revenue of Rs. 2,319.06 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 8% is okay, ROE of 7% is fair but needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 8% and 54% from 50DMA and 200DMA. IOLCP is a prominent player in the Indian specialty chemicals and pharmaceuticals sector, specializing in the manufacture of a wide range of products, including active pharmaceutical ingredients (APIs), solvents, and other chemical intermediates. With a strong emphasis on quality, IOL Chemicals adheres to stringent regulatory standards and employs advanced manufacturing processes to ensure the highest product standards. The company serves various industries, including pharmaceuticals, agrochemicals, and food processing, providing innovative and reliable solutions tailored to customer needs. Committed to sustainability and continuous improvement, IOL Chemicals aims to enhance its market presence both domestically and internationally. Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

IOLCP

This company is a global powerhouse, holding a 35% global market share in Ibuprofen. They are riding the "China Plus One" wave, as global buyers shift away from Chinese suppliers. Beyond Ibuprofen, they are expanding into specialty chemicals and other APIs with a strong focus on exports to 40+ countries. Their profits grew by 44% recently, significantly outpacing sales growth. My Analysis: This is a "good" candidate for defensive investors. Being a world leader in a specific drug gives them immense pricing power. The stock is fairly valued (PE 35), and their massive cash reserve of ₹190 crores provides a safety net for further expansion. It’s a clean, debt-free way to play the pharma recovery.

IOLCP

IOL CHEMICALS: CHINA APPROVES CLOPIDOGREL API 🇨🇳💊 • ✅ China's NMPA has approved IOL Chemicals' Clopidogrel Bisulfate API • 📅 Approval received on July 14, 2026 • 🌍 Approval is in addition to the company's existing CEP certification for the product • 📈 Strengthens regulatory portfolio and expands access to the Chinese pharmaceutical market 🟢 Impact: Positive (Enhances export opportunities and strengthens IOL Chemicals' presence in the regulated China market.)

IOL Chemicals & Pharmaceuticals Ltd. SWOT Analysis

IOLCP Strengths One of the world's leading manufacturers of the API (Active Pharmaceutical Ingredient) Ibuprofen, with an estimated global market share of around 35%. Diversified business across pharmaceutical APIs and specialty chemicals, reducing dependence on a single product line. Strong manufacturing capabilities with vertically integrated operations, supporting cost efficiency. Expanding API portfolio including products such as Metformin, Pantoprazole, Clopidogrel, Paracetamol, Losartan Potassium and others. Healthy balance sheet with relatively low debt and a consistent dividend payout history. Weaknesses Significant dependence on Ibuprofen exposes earnings to pricing and demand fluctuations. Profitability remains vulnerable to volatility in raw material and chemical prices. Return on equity has remained moderate compared with leading pharmaceutical peers. Revenue and earnings can fluctuate because of global API price cycles and export demand. High exposure to export markets results in foreign exchange risk. Opportunities Rising global demand for pharmaceutical APIs driven by increasing healthcare expenditure. Capacity expansion into higher-value APIs and specialty chemicals can improve margins. Growth opportunities through regulated markets such as the US, Europe and emerging economies. Increasing outsourcing of API manufacturing by multinational pharmaceutical companies. Government initiatives supporting domestic pharmaceutical manufacturing and the "China+1" sourcing strategy may benefit Indian API manufacturers. Threats Intense competition from Chinese API manufacturers leading to pricing pressure. Regulatory risks related to inspections by global drug regulators (USFDA, EU authorities, etc.). Volatility in crude oil derivatives and chemical feedstock costs. Currency fluctuations affecting export realizations. Environmental regulations and compliance costs for chemical manufacturing.